Jim Anderson, MPAS, PA-C, explores the role and limits of guidelines.
In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.
Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
Data from the GENIE registry revealed distinct genomic patterns in patients of different races/ethnicities.
One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
Enrollment rates varied widely by study type and institution.
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Dr Alan Lyss reviews studies of KRAS G12C mutations in metastatic colorectal cancer.
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Preferences are tied not just to the experience of receiving an injection, but also to factors related to a patient’s access to different types of care settings.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.